Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: Significance for subunit vaccines

Journal of Virology

Volumn 73, Issue 4, 1999, Pages 2956-2962

  Sakurai, Hiroshi ^a,b   Anthony Williamson, R ^a   Crowe, James E ^c   Beeler, Judy A ^d   Poignard, Pascal ^a   Bastidas, Raiza B ^a   Chanock, Robert M ^e   Burton, Dennis R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b KANEKA CORPORATION   (Japan)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; GLYCOPROTEIN; IMMUNOGLOBULIN G; VACCINE;

ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CYTOLYSIS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; VIRION; VIRUS ENVELOPE; VIRUS INFECTION;

EID: 0345369696     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.4.2956-2962.1999     Document Type: Article

References (41)

1. Barbas, C. F., T. A. Collet, W. Amberg, P. Roben, J. M. Binley, D. Hoekstra, D. Cababa, T. M. Jones, R. A. Williamson, G. R. Pilkington, N. L. Haigwood, E. Cabezas, A. C. Satterthwait, I. Sanz, and D. R. Burton. 1993. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J. Mol. Biol. 230:812-823.
2. Barbas, C. F., III, J. E. Crowe, Jr., D. Cababa, T. M. Jones, S. L. Zebedee, B. R. Murphy, R. M. Chanock, and D. R. Burton. 1992. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc. Natl. Acad. Sci. USA 89:10164-10168.
3. Beeler, J. A., and K. van Wyke Coelingh. 1989. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 63:2941-2950
4. Berman, P. W., A. M. Gray, T. Wrin, J. C. Vennari, D. J. Eastman, G. R. Nakamura, D. P. Francis, G. Gorse, and D. H. Schwartz. 1997. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J. Infect. Dis. 176:384-397.
5. Bourgeois, C., C. Corvaisier, J. B. Bour, E. Kohli, and P. Pothier. 1991. Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virus. J. Gen. Virol. 72:1051-1058.
6. Burton, D. R. 1997. A vaccine for HIV type 1: the antibody perspective. Proc. Natl. Acad. Sci. USA 94:10018-10023.
7. Burton, D. R., and C. F. Barbas. 1994. Human antibodies from combinatorial libraries. Adv. Immunol. 57:191-280.
8. Burton, D. R., C. F. Barbas, M. A. Persson, S. Koenig, R. M. Chanock, and R. A. Lerner. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88:10134-10137.
9. Caton, A. J., and H. Koprowski. 1990. Influenza virus hemagglutinin-specific antibodies isolated from a combinatorial expression library are closely related to the immune response of the donor. Proc. Natl. Acad. Sci. USA 87: 6450-6454.
10. Coates, H. V., D. W. Alling, and R. M. Chanock. 1966. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am. J. Epidemiol. 83:299-313.
11. Collins, P. L., and G. Mottet. 1991. Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus. J. Gen. Virol. 72:3095-3101.
12. Connor, R. I., B. T. M. Korber, B. S. Graham, B. H. Hahn, D. D. Ho, B. D. Walker, A. U. Neumann, S. H. Vermund, J. Mestecky, S. Jackson, E. Fenamore, Y. Cao, F. Gao, S. Kalams, K. J. Kunstman, D. McDonald, N. McWilliams, A. Trkola, J. P. Moore, and S. M. Wolinsky. 1998. Immunological and virological analyses of persons infected by human immunodefi-ciency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72:1552-1576.
13. Corbeil, S., C. Seguin, and M. Trudel. 1996. Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2. Vaccine 14:521-525.
14. Crowe, J. E., Jr., B. R. Murphy, R. M. Chanock, R. A. Williamson, C. F. Barbas, and D. R. Burton. 1994. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc. Natl. Acad. Sci. USA 91:1386-1390.
15. Crowe, J. E., Jr., P. T. Bui, A. R. Davis, R. M. Chanock, and B. R. Murphy. 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12:783-790.
16. Crowe, J. E., Jr., P. T. Bui, C. Y. Firestone, M. Connors, W. R. Elkins, R. M. Chanock, and B. R. Murphy. 1996. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. J. Infect. Dis. 173:829-539.
17. Dudas, R. A., and R. A. Karron. 1998. Respiratory syncytial virus vaccines. Clin. Microbiol. Rev. 11:430-439.
18. Falsey, A. R., and E. E. Walsh. 1996. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14:1214-1218.
19. Hexham, J. M., L. J. Partridge, J. Furmaniak, V. B. Petersen, J. C. Colls, C. A. S. Pegg, B. R. Smith, and D. R. Burton. 1994. Cloning and characterisation of TPO autoantibodies using combinatorial phage display libraries. Autoimmunity 17:167-179.
20. Jonsson, U., L. Fagerstam, B. Ivarsson, B. Johnsson, R. Karlsson, L. K. Lofas, B. Persson, H. Roos, and I. Ronnberg. 1991. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. BioTechniques 11:620-627.
21. Karron, R. A., D. A. Buonagurio, A. F. Georgia, S. A. Whitehead, J. E. Adamus, M. L. Clements-Mann, D. O. Harris, V. B. Randolph, S. A. Udem, B. R. Murphy, and M. S. Sidhu. 1997. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. USA 94:13961-13966.
22. Karron, R. A., P. F. Wright, J. E. Crowe, Jr., M. L. Clements-Mann, J. Thompson, M. Makhene, R. Casey, and B. R. Murphy. 1997. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis. 176:1428-1436.
23. Lopez, J. A., D. Andreu, C. Carreno, P. Whyte, G. Taylor, and J. A. Melero. 1993. Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein. J. Gen. Virol. 74:2567-2577.
24. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9(Suppl. A):S117-S136.
25. Murphy, B. R., and P. L. Collins. 1997. Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting. Bull. W. H. O. 75:307-313.
26. Murphy, B. R., S. L. Hall, A. B. Kulkarini, J. E. Crowe, Jr., P. L. Collins, M. Connors, R. A. Karron, and R. M. Chanock. 1994. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32:13-36.
27. Murphy, B. R., G. A. Rince, and E. E. Walsh. 1986. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microbiol. 24:197-202.
28. Null, D., C. Bimle, L. Weisman, K. Johnson, J. Steichen, S. Singh, and The Impact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531-537.
29. Parren, P. W., H. I., M.-C. Gauduin, R. A. Koup, P. Poignard, Q. J. Sattentau, P. Fisicaro, and D. R. Burton. 1997. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol. Lett. 58:125-132.
30. Parren, P. W. H. I., Q. J. Sattentau, and D. R. Burton. 1997 HIV-1 antibody-debris or virion? Nat. Med. 3:367-368.
31. Piedra, P. A., S. Grace, A. Jewell, S. Spinelli, D. Bunting, D. A. Hogerman, F. Malinoski, and P. W. Hiatt. 1996. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic librosis. Pediatr. Dis. J. 15:23-31.
32. Portolano, S., G. D. Chazenbalk, P. Seto, J. S. Hutchison, B. Rapoport, and S. M. McLachlan. 1992. Recognition by recombinant autoimmune thyroid disease-derived Fab fragments of a dominant conformational epitope on thyroid peroxidase. J. Clin. Investig. 90:720-726.
33. Prince, G. A., V. G. Hemming, R. L. Horswood, and R. M. Chanock. 1985. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 3:193-206.
34. Taylor, G., J. M. Furze, P. R. Tempest, P. Bremner, F. J. Carr, and W. J. Harris. 1991. Humanised monoclonal antibody to respiratory syncytial virus. Lancet 337:1411-1412.
35. Taylor, G., E. J. Stott, M. Bew, B. F. Fernie, P. J. Cote, A. P. Collins, M. Hugues, and J. Jerbett. 1984. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52:137-142.
36. Trudel, M., E. J. Stott, G. Taylor, D. Oth, G. Mercier, F. Nadon, C. Séguin, C. Simard, and M. Lacroix. 1991. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection. Arch. Virol. 117:59-71.
37. Tsui, P., M. A. Tornetta, R. S. Ames, B. C. Bankosky, S. Griego, C. Silverman, T. Porter, G. Moore, and R. W. Sweet. 1996. Isolation of a neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning. J. Immunol. 157:772-780.
38. Tsui, P., M. A. Tornetta, R. S. Ames, B. C. Bankosky, S. Griego, C. Silverman, T. Porter, G. Moore, and R. W. Sweet. 1996. Isolation of RSV specific neutralizing human antibodies via blocked panning of Fab combinatorial phage libraries, p. 149-153. In F. Brown, D. R. Burton, J. Mekalanos, and E. Norrby (ed.), Vaccines 96: molecular approaches to the control of infectious diseases. Cold Spring Harbor Laboratory Press, Plainview, N. Y.
39. Walsh, E. E., J. J. Schlesinger, and M. W. Brandriss. 1984. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect. Immun. 43:756-758.
40. Weltzin, R., S. A. Hsu, E. S. Mittler, K. Georgakopoulos, and T. P. Monath. 1994. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob. Agents Chemother. 38:2785-2791.
41. Williamson, R. A., R. Burioni, P. P. Sanna, L. J. Partridge, C. F. Barbas, and D. R. Burton. 1993. Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc. Natl. Acad. Sci. USA 90: 4141-4145.